Amgen (AMGN) : St. Johns Investment Management Company scooped up 71 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 17, 2016. The investment management firm now holds a total of 8,222 shares of Amgen which is valued at $1,331,142.Amgen makes up approximately 1.13% of St. Johns Investment Management Company’s portfolio.
Other Hedge Funds, Including , Crestpoint Capital Management reduced its stake in AMGN by selling 5,600 shares or 38.62% in the most recent quarter. The Hedge Fund company now holds 8,900 shares of AMGN which is valued at $1,440,910. Amgen makes up approx 0.75% of Crestpoint Capital Management’s portfolio.Sarasin Partners Llp boosted its stake in AMGN in the latest quarter, The investment management firm added 18,141 additional shares and now holds a total of 1,339,865 shares of Amgen which is valued at $216,924,144. Amgen makes up approx 3.46% of Sarasin Partners Llp’s portfolio.Legal General Group Plc boosted its stake in AMGN in the latest quarter, The investment management firm added 26,550 additional shares and now holds a total of 3,449,758 shares of Amgen which is valued at $566,864,235. Amgen makes up approx 0.58% of Legal General Group Plc’s portfolio. Contravisory Investment Management sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 13 shares of AMGN which is valued $2,188.Central Bank Trust Co reduced its stake in AMGN by selling 283 shares or 2.34% in the most recent quarter. The Hedge Fund company now holds 11,820 shares of AMGN which is valued at $1,979,850. Amgen makes up approx 0.56% of Central Bank Trust Co’s portfolio.
Amgen closed down -2.39 points or -1.45% at $161.9 with 28,17,469 shares getting traded on Friday. Post opening the session at $165.05, the shares hit an intraday low of $161.84 and an intraday high of $165.25 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Investors should note that on Oct 14, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Nov 14, 2016 as the ex-dividend date and fixed the record date on Nov 16, 2016. The payable date has been fixed on Dec 8, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.